Fate Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Fate Therapeutics

12/11/2024 23:31

* Fate Therapeutics Inc  FATE.OQ  reported a quarterly
adjusted
loss of 40 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -46 cents.  The mean expectation of
nineteen analysts for the quarter was for a loss of 43 cents per
share. Wall Street expected results to range from -66 cents
to -37 cents per share.
    * Revenue rose 58.1% to $3.07 million from a year ago;
analysts
expected $1.33 million. 
    * Fate Therapeutics Inc's reported EPS for the quarter was a
loss
of 40 cents​.
    * The company reported a quarterly loss of $47.68 million.
    * Fate Therapeutics Inc shares had fallen by 26.9% this
quarter and lost 31.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 4.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 11
"hold" and 1 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Fate Therapeutics
Inc is $5.50 
This summary was machine generated from LSEG data November 12 at
11:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.43          -0.40          Beat
 Jun. 30 2024      -0.48          -0.33          Beat
 Mar. 31 2024      -0.49          -0.47          Beat
 Dec. 31 2023      -0.52          -0.45          Beat